Calidi Biotherapeutics (NYSE:CLDI) Stock Price Down 8.2% – Should You Sell?

Calidi Biotherapeutics, Inc. (NYSE:CLDI)’s stock price traded down 8.2% during trading on Wednesday . The stock traded as low as $1.30 and last traded at $1.35. 1,961,157 shares traded hands during trading, an increase of 37% from the average session volume of 1,435,489 shares. The stock had previously closed at $1.47.

Calidi Biotherapeutics Stock Down 8.2 %

The firm has a fifty day moving average of $1.75.

Calidi Biotherapeutics (NYSE:CLDI) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.20. Research analysts forecast that Calidi Biotherapeutics, Inc. will post -4.48 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Calidi Biotherapeutics stock. RS Crum Inc. raised its stake in Calidi Biotherapeutics, Inc. (NYSE:CLDI) by 2,327.4% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 263,470 shares of the company’s stock after acquiring an additional 252,616 shares during the quarter. RS Crum Inc. owned approximately 0.52% of Calidi Biotherapeutics worth $53,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 12.53% of the company’s stock.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.